Ensysce Biosciences Q1 2024 GAAP EPS $(0.55) Beats $(0.90) Estimate, Sales $305.722K Miss $400.000K Estimate
Ensysce Biosciences Q1 2024 GAAP EPS $(0.55) Beats $(0.90) Estimate, Sales $305.722K Miss $400.000K Estimate
Ensysce Biosciences 2024年第一季度GAAP每股收益（0.55）超过预期（0.90），销售额为305.722万美元，未达到400.000万美元的预期
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.90) by 38.89 percent. The company reported quarterly sales of $305.722 thousand which missed the analyst consensus estimate of $400.000 thousand by 23.57 percent. This is a 61.28 percent decrease over sales of $789.635 thousand the same period last year.
Ensysce Biosciences（纳斯达克股票代码：ENSC）公布的季度亏损为每股0.55美元，比分析师普遍预期的0.90美元（0.90美元）高出38.89％。该公司公布的季度销售额为305,722美元，比分析师普遍预期的40万美元低23.57％。这比去年同期的789,635美元的销售额下降了61.28％。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。